Skip to main content
Erschienen in: Journal of Neurology 2/2024

21.10.2023 | Original Communication

Cardiac sympathetic “morbidity” might reflect the neurobiology of early Parkinson’s disease

verfasst von: Sang-Won Yoo, Yoon-Sang Oh, Dong-Woo Ryu, Seunggyun Ha, Chul Hyoung Lyoo, Yuna Kim, Ji-Yeon Yoo, Joong-Seok Kim

Erschienen in: Journal of Neurology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

An appropriate extracranial biomarker that delineates endophenotypes of Parkinson’s disease (PD) at an early stage and reflects the neurodegenerative process is lacking. An evaluation of myocardial sympathetic nerve terminals could be a good candidate. This study aimed to explore subtypes of PD patients that showed cardiac catecholaminergic vesicular defect and their characteristics.

Methods

This study included 122 early drug-naïve PD patients who were followed for approximately 4–5 years. All patients were examined with 18F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl) nortropane positron-emission tomography and 123I-meta-iodobenzylguanidine myocardial scintigraphy. Cardiac scans were reexamined two or three times. Patients were subgrouped into the sympathetic denervated group at the initial scan, those without evidence of denervated myocardium in the first and subsequent scans, and the converters whose myocardium was initially normal but became impaired in the subsequent scans. Cognition in 99 patients was initially assessed with neuropsychological tests. Any associations between cardiac denervation subtypes and presynaptic dopamine transporter densities were investigated. Cognitive status relevant to cardiac sympathetic denervation status was evaluated.

Results

This study found that cross-sectional comparisons of presynaptic monoamine transporter availability with a predefined order of cardiac denervation groups revealed parallel degeneration. A quadratic correlation between cardiac catecholamine capacity and cognition was observed. This association was interpreted to reflect the early neurobiology of PD.

Conclusion

An observed cardiac catecholaminergic gradient was to mirror the central neurobiology of early PD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov disord 30(12):1591–1601CrossRefPubMed Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov disord 30(12):1591–1601CrossRefPubMed
2.
Zurück zum Zitat Orimo S, Yogo M, Nakamura T, Suzuki M, Watanabe H (2016) (123)I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in alpha-synucleinopathies. Ageing Res Rev 30:122–133CrossRefPubMed Orimo S, Yogo M, Nakamura T, Suzuki M, Watanabe H (2016) (123)I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in alpha-synucleinopathies. Ageing Res Rev 30:122–133CrossRefPubMed
3.
Zurück zum Zitat Kim JS, Park HE, Park IS, Oh YS, Ryu DW, Song IU et al (2017) Normal “heart” in Parkinson’s disease: is this a distinct clinical phenotype? Eur J Neurol 24(2):349–356CrossRefPubMed Kim JS, Park HE, Park IS, Oh YS, Ryu DW, Song IU et al (2017) Normal “heart” in Parkinson’s disease: is this a distinct clinical phenotype? Eur J Neurol 24(2):349–356CrossRefPubMed
4.
Zurück zum Zitat Yoo SW, Kim JS, Oh YS, Ryu DW, Ha S, Yoo JY et al (2021) Cardiac sympathetic burden reflects Parkinson disease burden, regardless of high or low orthostatic blood pressure changes. NPJ Parkinsons Dis 7(1):71CrossRefPubMedPubMedCentral Yoo SW, Kim JS, Oh YS, Ryu DW, Ha S, Yoo JY et al (2021) Cardiac sympathetic burden reflects Parkinson disease burden, regardless of high or low orthostatic blood pressure changes. NPJ Parkinsons Dis 7(1):71CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Goldstein DS, Sewell L, Sharabi Y (2011) Autonomic dysfunction in PD: a window to early detection? J Neurol Sci 310(1–2):118–122CrossRefPubMed Goldstein DS, Sewell L, Sharabi Y (2011) Autonomic dysfunction in PD: a window to early detection? J Neurol Sci 310(1–2):118–122CrossRefPubMed
6.
Zurück zum Zitat Jain S, Goldstein DS (2012) Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis 46(3):572–580CrossRefPubMed Jain S, Goldstein DS (2012) Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis 46(3):572–580CrossRefPubMed
7.
Zurück zum Zitat Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Terada H, Inaoka T (2014) MIBG myocardial scintigraphy in pre-motor Parkinson’s disease: a review. Parkinsonism Relat Disord 20(3):267–273CrossRefPubMed Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Terada H, Inaoka T (2014) MIBG myocardial scintigraphy in pre-motor Parkinson’s disease: a review. Parkinsonism Relat Disord 20(3):267–273CrossRefPubMed
8.
Zurück zum Zitat Tsujikawa K, Hasegawa Y, Yokoi S, Yasui K, Nanbu I, Yanagi T et al (2015) Chronological changes of 123I-MIBG myocardial scintigraphy and clinical features of Parkinson’s disease. J Neurol Neurosurg Psychiatry 86(9):945–951CrossRefPubMed Tsujikawa K, Hasegawa Y, Yokoi S, Yasui K, Nanbu I, Yanagi T et al (2015) Chronological changes of 123I-MIBG myocardial scintigraphy and clinical features of Parkinson’s disease. J Neurol Neurosurg Psychiatry 86(9):945–951CrossRefPubMed
9.
Zurück zum Zitat Nakajima K, Taki J, Tonami N, Hisada K (1994) Decreased 123I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun 15(5):317–323CrossRefPubMed Nakajima K, Taki J, Tonami N, Hisada K (1994) Decreased 123I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun 15(5):317–323CrossRefPubMed
10.
Zurück zum Zitat Goldstein DS, Sharabi Y (2019) The heart of PD: Lewy body diseases as neurocardiologic disorders. Brain Res 1702:74–84CrossRefPubMed Goldstein DS, Sharabi Y (2019) The heart of PD: Lewy body diseases as neurocardiologic disorders. Brain Res 1702:74–84CrossRefPubMed
11.
Zurück zum Zitat Goldstein DS (2020) The “Sick-but-not-Dead” phenomenon applied to catecholamine deficiency in neurodegenerative diseases. Semin Neurol 40(5):502–514CrossRefPubMedPubMedCentral Goldstein DS (2020) The “Sick-but-not-Dead” phenomenon applied to catecholamine deficiency in neurodegenerative diseases. Semin Neurol 40(5):502–514CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Jankovic J (2005) Progression of Parkinson disease: are we making progress in charting the course? Arch Neurol 62(3):351–352CrossRefPubMed Jankovic J (2005) Progression of Parkinson disease: are we making progress in charting the course? Arch Neurol 62(3):351–352CrossRefPubMed
13.
Zurück zum Zitat Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51(6):745–752CrossRefPubMedPubMedCentral Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51(6):745–752CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Ryu DW, Kim JS, Lee JE, Oh YS, Yoo SW, Yoo IR et al (2019) Initial versus follow-up sequential myocardial 123I-MIBG scintigraphy to discriminate Parkinson disease from atypical Parkinsonian syndromes. Clin Nucl Med 44(4):282–288CrossRefPubMed Ryu DW, Kim JS, Lee JE, Oh YS, Yoo SW, Yoo IR et al (2019) Initial versus follow-up sequential myocardial 123I-MIBG scintigraphy to discriminate Parkinson disease from atypical Parkinsonian syndromes. Clin Nucl Med 44(4):282–288CrossRefPubMed
15.
Zurück zum Zitat Cho H, Kim JS, Choi JY, Ryu YH, Lyoo CH (2014) A computed tomography-based spatial normalization for the analysis of [18F] fluorodeoxyglucose positron emission tomography of the brain. Korean J Radiol 15(6):862–870CrossRefPubMedPubMedCentral Cho H, Kim JS, Choi JY, Ryu YH, Lyoo CH (2014) A computed tomography-based spatial normalization for the analysis of [18F] fluorodeoxyglucose positron emission tomography of the brain. Korean J Radiol 15(6):862–870CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Kim JS, Cho H, Choi JY, Lee SH, Ryu YH, Lyoo CH et al (2015) Feasibility of computed tomography-guided methods for spatial normalization of dopamine transporter positron emission tomography image. PLoS One 10(7):e0132585CrossRefPubMedPubMedCentral Kim JS, Cho H, Choi JY, Lee SH, Ryu YH, Lyoo CH et al (2015) Feasibility of computed tomography-guided methods for spatial normalization of dopamine transporter positron emission tomography image. PLoS One 10(7):e0132585CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Ryu HJ, Yang DW (2023) The Seoul neuropsychological screening battery (SNSB) for comprehensive neuropsychological assessment. Dement Neurocogn Disord 22:1–15CrossRefPubMedPubMedCentral Ryu HJ, Yang DW (2023) The Seoul neuropsychological screening battery (SNSB) for comprehensive neuropsychological assessment. Dement Neurocogn Disord 22:1–15CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord 27(3):349–356CrossRefPubMedPubMedCentral Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord 27(3):349–356CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Goldman JG, Holden S, Ouyang B, Bernard B, Goetz CG, Stebbins GT (2015) Diagnosing PD-MCI by MDS task force criteria: how many and which neuropsychological tests? Mov Disord 30(3):402–406CrossRefPubMed Goldman JG, Holden S, Ouyang B, Bernard B, Goetz CG, Stebbins GT (2015) Diagnosing PD-MCI by MDS task force criteria: how many and which neuropsychological tests? Mov Disord 30(3):402–406CrossRefPubMed
20.
Zurück zum Zitat Miller IN, Neargarder S, Risi MM, Cronin-Golomb A (2013) Frontal and posterior subtypes of neuropsychological deficit in Parkinson’s disease. Behav Neurosci 127(2):175–183CrossRefPubMedPubMedCentral Miller IN, Neargarder S, Risi MM, Cronin-Golomb A (2013) Frontal and posterior subtypes of neuropsychological deficit in Parkinson’s disease. Behav Neurosci 127(2):175–183CrossRefPubMedPubMedCentral
21.
22.
Zurück zum Zitat Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130(Pt 7):1787–1798CrossRefPubMed Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130(Pt 7):1787–1798CrossRefPubMed
23.
Zurück zum Zitat Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J et al (2011) Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson’s disease. Brain 134(Pt 11):3290–3298CrossRefPubMed Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J et al (2011) Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson’s disease. Brain 134(Pt 11):3290–3298CrossRefPubMed
24.
Zurück zum Zitat Prange S, Danaila T, Laurencin C, Caire C, Metereau E, Merle H et al (2019) Age and time course of long-term motor and nonmotor complications in Parkinson disease. Neurology 92(2):e148–e160CrossRefPubMed Prange S, Danaila T, Laurencin C, Caire C, Metereau E, Merle H et al (2019) Age and time course of long-term motor and nonmotor complications in Parkinson disease. Neurology 92(2):e148–e160CrossRefPubMed
25.
Zurück zum Zitat Coughlin DG, Hurtig HI, Irwin DJ (2020) Pathological influences on clinical heterogeneity in Lewy body diseases. Mov Disord 35(1):5–19CrossRefPubMed Coughlin DG, Hurtig HI, Irwin DJ (2020) Pathological influences on clinical heterogeneity in Lewy body diseases. Mov Disord 35(1):5–19CrossRefPubMed
26.
28.
Zurück zum Zitat O’Keeffe GW, Sullivan AM (2018) Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson’s disease. Parkinsonism Relat Disord 56:9–15CrossRefPubMed O’Keeffe GW, Sullivan AM (2018) Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson’s disease. Parkinsonism Relat Disord 56:9–15CrossRefPubMed
29.
Zurück zum Zitat Phan JA, Stokholm K, Zareba-Paslawska J, Jakobsen S, Vang K, Gjedde A et al (2017) Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson’s disease. Sci Rep 7(1):6363CrossRefPubMedPubMedCentral Phan JA, Stokholm K, Zareba-Paslawska J, Jakobsen S, Vang K, Gjedde A et al (2017) Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson’s disease. Sci Rep 7(1):6363CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T et al (2005) Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 109(6):583–588CrossRefPubMed Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T et al (2005) Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 109(6):583–588CrossRefPubMed
31.
Zurück zum Zitat Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K et al (2007) Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson’s disease. Brain Pathol 17(1):24–30CrossRefPubMedPubMedCentral Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K et al (2007) Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson’s disease. Brain Pathol 17(1):24–30CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Lee JE, Kim JS, Ryu DW, Oh YS, Yoo IR, Lee KS (2018) Cardiac sympathetic denervation can predict the wearing-off phenomenon in patients with Parkinson disease. J Nucl Med 59(11):1728–1733CrossRefPubMed Lee JE, Kim JS, Ryu DW, Oh YS, Yoo IR, Lee KS (2018) Cardiac sympathetic denervation can predict the wearing-off phenomenon in patients with Parkinson disease. J Nucl Med 59(11):1728–1733CrossRefPubMed
33.
Zurück zum Zitat Sara SJ (2009) The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 10(3):211–223CrossRefPubMed Sara SJ (2009) The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 10(3):211–223CrossRefPubMed
34.
Zurück zum Zitat Brooks DJ, Piccini P (2006) Imaging in Parkinson’s disease: the role of monoamines in behavior. Biol Psychiatry 59(10):908–918CrossRefPubMed Brooks DJ, Piccini P (2006) Imaging in Parkinson’s disease: the role of monoamines in behavior. Biol Psychiatry 59(10):908–918CrossRefPubMed
35.
Zurück zum Zitat Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJ, Kraneveld AD (2017) Exploring Braak’s hypothesis of Parkinson’s disease. Front Neurol 8:37CrossRefPubMedPubMedCentral Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJ, Kraneveld AD (2017) Exploring Braak’s hypothesis of Parkinson’s disease. Front Neurol 8:37CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211CrossRefPubMed Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211CrossRefPubMed
37.
Zurück zum Zitat Horsager J, Andersen KB, Knudsen K, Skjaerbaek C, Fedorova TD, Okkels N et al (2020) Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study. Brain 143(10):3077–3088CrossRefPubMed Horsager J, Andersen KB, Knudsen K, Skjaerbaek C, Fedorova TD, Okkels N et al (2020) Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study. Brain 143(10):3077–3088CrossRefPubMed
39.
Zurück zum Zitat Fearon C, Lang A, Espay A (2021) The logic and pitfalls of Parkinson’s as brain- versus body-first subtypes. Mov Disord 36(3):594–598CrossRefPubMed Fearon C, Lang A, Espay A (2021) The logic and pitfalls of Parkinson’s as brain- versus body-first subtypes. Mov Disord 36(3):594–598CrossRefPubMed
40.
Zurück zum Zitat Lang AE, Espay AJ (2018) Disease modification in Parkinson’s disease: current approaches, challenges, and future considerations. Mov Disord 33(5):660–677CrossRefPubMed Lang AE, Espay AJ (2018) Disease modification in Parkinson’s disease: current approaches, challenges, and future considerations. Mov Disord 33(5):660–677CrossRefPubMed
Metadaten
Titel
Cardiac sympathetic “morbidity” might reflect the neurobiology of early Parkinson’s disease
verfasst von
Sang-Won Yoo
Yoon-Sang Oh
Dong-Woo Ryu
Seunggyun Ha
Chul Hyoung Lyoo
Yuna Kim
Ji-Yeon Yoo
Joong-Seok Kim
Publikationsdatum
21.10.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 2/2024
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-023-12049-7

Weitere Artikel der Ausgabe 2/2024

Journal of Neurology 2/2024 Zur Ausgabe

Neurological Update

Neurosarcoidosis

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.